BBIO BridgeBio Pharma, Inc.

Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.

Earlier this week, BridgeBio Pharma reported peer-reviewed real-world data in Cardiology and Therapy showing that its ATTR cardiomyopathy therapy acoramidis was associated with lower early clinical worsening risk versus tafamidis in newly treated patients over a mean follow-up of 4.6 months. The study offers the first head-to-head, real-world comparison between approved transthyretin stabilizers, potentially strengthening the clinical and commercial positioning of acoramidis as Attruby in...

BridgeBio Pharma has delivered a strong share price run in recent years, and that kind of move naturally raises the question of whether the current valuation still lines up with the sales that sit behind the story. With fresh real world data around its acoramidis therapy now in the mix, investors are asking how much revenue power is realistically being priced into the stock today. Over the past 3 years the stock has gained 148.7%, which puts real pressure on the question of how much sales...

BridgeBio Pharma (NASDAQ:BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a Bernstein discussion. Trimarchi said the company’s strategy centers on developing medicines for gen

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is asking investors to look beyond disease stabilization in transthyretin amyloid cardiomyopathy, or ATTR-CM. New cardiac magnetic resonance imaging data from the Phase 3 ATTRibute-CM study and its open-label extension suggested that some acoramidis-treated patients experienced improvements in cardiac structure and function. A separate post-hoc analysis found that treatment preserved more […]

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices. The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL,...

BridgeBio Pharma (NasdaqGS:BBIO) has entered a voluntary agreement with the U.S. government to expand access to its medicines and lower drug costs for American patients. The arrangement widens Medicaid access through a unique pricing and reimbursement model tailored to public health programs. The agreement keeps current Medicare Part D offerings in place without new pricing mandates on those products. Orphan indication drugs are excluded from future pricing commitments under this framework,...

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.

These deals will require the companies to provide MFN prices to state Medicaid programmes nationally.

BridgeBio Pharma has delivered a strong share price gain over the past three years, yet its current checks suggest the stock now looks closer to fairly valued than obviously cheap. With recent news around its ATTR-CM therapy acoramidis keeping expectations high, the question for investors is how much of that optimism is already reflected in the price. The stock is up 158.6% over three years, which sets a high bar for further returns after such a strong run. Progress on acoramidis, including...

Under the deals, the drug makers would charge Americans no more than the lowest price paid in other rich countries.

The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said

The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd.

BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.

BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, continued losses and launch risks.

BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 161 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Up

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

Attruby revenue surged to $222.4 million as three pipeline programs entered regulatory review.

BridgeBio Pharma (NasdaqGS:BBIO) reports recent clinical and regulatory milestones across late-stage rare disease assets, including acoramidis, BBP-418, and encaleret. Acoramidis continues to show differentiated efficacy signals in ATTR-CM based on recent late-phase data and real-world findings. BBP-418 for LGMD2I/R9 and encaleret for ADH1 each receive Priority Review status, with BBP-418 positioned as a first potential therapy for its indication. Recent progress supports BridgeBio Pharma’s...

The company clearly has a winner on its hands with the recently approved Attruby.

BridgeBio Pharma's (BBIO) transition into a rare disease "commercial powerhouse" is on track and poi

BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

BridgeBio Pharma Inc (BBIO) posts record $243.7M quarterly revenue, driven by Attruby's explosive growth and a $1B financing boost, while advancing three FDA-accepted NDAs toward a pivotal 2027.

Moby summary of BridgeBio Pharma, Inc.'s Q2 2026 earnings call

BridgeBio Pharma (NASDAQ:BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review and expanding commercial preparations for potential launches over the next year. Chief Executive Off

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.88% and +9.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.

BridgeBio Pharma stock has delivered a very strong 147.9% return over the past three years, yet its current checks lean expensive rather than clearly cheap. With a key drug candidate progressing through the US approval process and the valuation screen showing a low score, investors are weighing how much of the story is already reflected in the price. The 147.9% three year return highlights how much optimism has already been priced into BridgeBio Pharma. The FDA acceptance of the New Drug...

The FDA has accepted BridgeBio Pharma's New Drug Application for encaleret for autosomal dominant hypocalcemia type 1. The filing includes pivotal trial data for a potential first approved therapy that targets the underlying genetic cause of ADH1. The agency has assigned a target action date, starting the formal review process for encaleret. BridgeBio Pharma, traded as NasdaqGS:BBIO, now has a key regulatory file under active FDA review with encaleret for ADH1. The stock closed at $79.96,...

Why BridgeBio Pharma Stock Is Back In Focus BridgeBio Pharma (BBIO) is back on investor radars after filing two shelf registrations totaling about US$2.21b in common stock, alongside detailed updates on its late stage encaleret program for ADH1 and chronic hypoparathyroidism. See our latest analysis for BridgeBio Pharma. BridgeBio Pharma shares trade at US$80.09 after a recent 1 day share price return that declined 2.5%, although the 3 month share price return of 16.82% and 1 year total...

Rapid commercial momentum could justify Wall Street's bullish outlook.

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BBIO's FDA filing for encaleret in ADH1 has been accepted, moving the rare disease candidate closer to a decision expected by May 2027.

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.